Investor Relations

Latest Presentation

Recent Event

Jefferies London Healthcare Conference

Nov 17, 2021 • 8:40 am - 9:15 am EST

Latest Financial Results

Q3 2021

Quarter Ended Jun 30, 2021

Latest Annual Filing

For Year Ending September 30, 2020

Company Overview

NeuBase Therapeutics, Inc. is developing its modular peptide-nucleic acid antisense oligonucleotide (PATrOL™) platform to address genetic diseases caused by mutant proteins with a single, cohesive approach. The systemically-deliverable PATrOL therapies have the potential to improve upon current gene silencing treatments by combining the advantages of synthetic approaches with the precision of antisense technologies. NeuBase intends to use its platform to address repeat expansion disorders, with an initial focus on Huntington’s disease and myotonic dystrophy, as well as a variety of other genetic disorders.

Investor Contact Information


NeuBase Therapeutics, Inc.
350 Technology Drive
Pittsburgh, PA 15219
T: 646-450-1790

Investor Relations

LifeSci Advisors, LLC
Dan Ferry
1 International Place
14th Floor
Boston, MA 02110
T: 617-535-7746

Transfer Agent

Standard Registrar and Transfer Company
440 East 400 South
Suite 200
Salt Lake City, UT 84111
T: 801-571-8844